Advertisement
A or MTD or TMO
Which Stock Would AI Choose? Agilent Technologies (A) vs. Mettler-Toledo International (MTD) vs. Thermo Fisher Scientific (TMO) Stock Comparison
Key Takeaways
- TMO boasts the largest market capitalization at approximately $174 billion, offering scale and diversification across instruments, consumables, and services in the life sciences sector.
- A presents the highest analyst price target upside, with targets implying over 40% potential appreciation amid softer recent demand signals.
- MTD maintains premium margins above 20% and strong one-year returns around 16%, though it faces scrutiny ahead of quarterly results.
- All three stocks have experienced year-to-date declines amid biopharmaceutical capital expenditure slowdowns, with TMO down nearly 19% and A showing three-month weakness of about 15%.
- Recent earnings for TMO and A highlighted resilient revenue growth despite sector headwinds, while MTD anticipates modest EPS expansion.
- Valuation metrics vary, with A and TMO trading at forward P/E ratios (price-to-earnings) in the mid-20s to low-30s, compared to MTD's higher multiple near 30.
Introduction
A, MTD, and TMO are leading providers of precision instruments and solutions for life sciences, pharmaceuticals, and diagnostics. This comparison analyzes their business models, recent performance, and market positioning amid a challenging environment marked by biopharma spending caution. Traders seeking short-term momentum and long-term investors eyeing healthcare equipment exposure will find insights into relative strengths, valuation trade-offs, and sector dynamics relevant for portfolio decisions.
A Overview and Recent Performance
Agilent Technologies (A) specializes in life sciences, diagnostics, and applied chemical markets, offering analytical instruments, software, and services for drug development and quality control. In recent market activity, the stock has traded in the mid-110s range, reflecting pressure from slowed demand in biopharma and diagnostics segments. Q1 fiscal 2026 revenue came in at $1.8 billion, slightly below expectations, influenced by macroeconomic caution and inventory adjustments. Sentiment has been tempered by these dynamics, though analysts maintain a consensus buy rating with a $164 average target, signaling potential recovery as end-market spending stabilizes.
MTD Overview and Recent Performance
Mettler-Toledo International (MTD) focuses on precision instruments like laboratory balances, pipettes, and analytical systems for research, pharma, and industrial applications. The stock, around $1,270 in recent weeks, has shown resilience with one-year gains near 16%, but year-to-date it lags amid broader sector softness. High profit margins exceeding 21% underscore operational efficiency, yet upcoming Q1 results face scrutiny over revenue growth stagnation. Key influences include end-user budget constraints in life sciences, with analysts projecting modest EPS growth and an overweight consensus at a $1,488 target.
TMO Overview and Recent Performance
Thermo Fisher Scientific (TMO), the sector giant, delivers a broad portfolio of instruments, consumables, reagents, and biopharma services. Recent trading has seen shares near $470, down sharply year-to-date by about 19% due to biopharma capex reductions, despite Q1 revenue growth of 6% to $11 billion and adjusted EPS beating estimates. Positive catalysts include a $1 billion divestiture of its microbiology unit and expansions in bioprocess facilities. Lower beta (0.88, a measure of volatility relative to the market) supports stability, with buy ratings and a $620 target reflecting optimism for diversified recovery.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases 25 top-performing AI trading bots curated from over 350 available on the platform, which collectively trade thousands of tickers across stocks, ETFs, and crypto. These bots employ diverse strategies like AI/ML-driven trend following, swing trading, and risk-managed corridors (e.g., 3% take-profit/2% stop-loss), delivering standout stats: annualized returns up to 163%, win rates from 51% to 88%, profit factors to 11.7, and trade durations from 1 day to 49 days. Examples target semiconductors (NVDA, AMD), space stocks (ASTS, PL), and financial ETFs. Ideal for current volatile conditions, they adapt via real-time signals. Explore Tickeron’s bots to align with your trading style and market outlook.
Head-to-Head Comparison
Business models differ notably: TMO emphasizes recurring consumables and services for stable revenue, while A and MTD lean on high-margin instruments vulnerable to capex cycles. Growth drivers include biopharma R&D, but recent momentum favors MTD’s one-year outperformance versus TMO’s declines. Risk factors center on sector exposure to biotech funding, with A showing higher volatility. Valuation sensitivity highlights A’s attractive upside versus MTD’s premium P/E; market sentiment tilts toward TMO for its scale amid trade-offs in growth consistency.
Tickeron AI Verdict
Tickeron’s AI currently favors TMO due to its earnings resilience, lower beta for stability, and catalysts like bioprocess expansions positioning it ahead in a recovering life sciences landscape. While A offers value and MTD strong margins, TMO’s relative trend consistency and scale suggest higher probability of outperformance in the near term.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 1 FA rating(s) are green whileMTD’s FA Score has 1 green FA rating(s), and TMO’s FA Score reflects 0 green FA rating(s).
- A’s FA Score: 1 green, 4 red.
- MTD’s FA Score: 1 green, 4 red.
- TMO’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 4 TA indicator(s) are bullish while MTD’s TA Score has 4 bullish TA indicator(s), and TMO’s TA Score reflects 4 bullish TA indicator(s).
- A’s TA Score: 4 bullish, 5 bearish.
- MTD’s TA Score: 4 bullish, 6 bearish.
- TMO’s TA Score: 4 bullish, 6 bearish.
Price Growth
A (@Medical Specialties) experienced а -3.39% price change this week, while MTD (@Medical Specialties) price change was -8.25% , and TMO (@Medical Specialties) price fluctuated -5.73% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +10.58%. For the same industry, the average monthly price growth was +4.66%, and the average quarterly price growth was -5.70%.
Reported Earning Dates
A is expected to report earnings on May 27, 2026.
MTD is expected to report earnings on Jul 23, 2026.
TMO is expected to report earnings on Jul 29, 2026.
Industries' Descriptions
@Medical Specialties (+10.58% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| A | MTD | TMO | |
| Capitalization | 31.6B | 20.8B | 163B |
| EBITDA | 1.82B | 1.24B | 11.7B |
| Gain YTD | -17.576 | -26.004 | -24.278 |
| P/E Ratio | 24.66 | 24.23 | 24.10 |
| Revenue | 7.07B | 4.03B | 45.2B |
| Total Cash | 1.76B | 66.9M | 3.26B |
| Total Debt | 3.35B | 2.15B | 43.2B |
A | MTD | TMO | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 13 | 52 | 58 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 19 Undervalued | 99 Overvalued | 39 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | 100 | |
SMR RATING 1..100 | 45 | 3 | 60 | |
PRICE GROWTH RATING 1..100 | 63 | 65 | 64 | |
P/E GROWTH RATING 1..100 | 53 | 65 | 46 | |
SEASONALITY SCORE 1..100 | 50 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
A's Valuation (19) in the Biotechnology industry is in the same range as TMO (39) in the Medical Specialties industry, and is significantly better than the same rating for MTD (99) in the Medical Specialties industry. This means that A's stock grew similarly to TMO’s and significantly faster than MTD’s over the last 12 months.
A's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as TMO (100) in the Medical Specialties industry, and is in the same range as MTD (100) in the Medical Specialties industry. This means that A's stock grew similarly to TMO’s and similarly to MTD’s over the last 12 months.
MTD's SMR Rating (3) in the Medical Specialties industry is somewhat better than the same rating for A (45) in the Biotechnology industry, and is somewhat better than the same rating for TMO (60) in the Medical Specialties industry. This means that MTD's stock grew somewhat faster than A’s and somewhat faster than TMO’s over the last 12 months.
A's Price Growth Rating (63) in the Biotechnology industry is in the same range as TMO (64) in the Medical Specialties industry, and is in the same range as MTD (65) in the Medical Specialties industry. This means that A's stock grew similarly to TMO’s and similarly to MTD’s over the last 12 months.
TMO's P/E Growth Rating (46) in the Medical Specialties industry is in the same range as A (53) in the Biotechnology industry, and is in the same range as MTD (65) in the Medical Specialties industry. This means that TMO's stock grew similarly to A’s and similarly to MTD’s over the last 12 months.
| A | MTD | TMO | |
|---|---|---|---|
| RSI ODDS (%) | N/A | 3 days ago 75% | 3 days ago 45% |
| Stochastic ODDS (%) | 3 days ago 53% | 3 days ago 69% | 3 days ago 60% |
| Momentum ODDS (%) | 3 days ago 56% | 3 days ago 62% | 3 days ago 56% |
| MACD ODDS (%) | 3 days ago 55% | 3 days ago 67% | 3 days ago 64% |
| TrendWeek ODDS (%) | 3 days ago 64% | 3 days ago 63% | 3 days ago 60% |
| TrendMonth ODDS (%) | 3 days ago 65% | 3 days ago 66% | 3 days ago 66% |
| Advances ODDS (%) | 11 days ago 61% | 12 days ago 63% | 11 days ago 63% |
| Declines ODDS (%) | 7 days ago 62% | 5 days ago 63% | 7 days ago 63% |
| BollingerBands ODDS (%) | 3 days ago 61% | 3 days ago 74% | 3 days ago 53% |
| Aroon ODDS (%) | 3 days ago 61% | 3 days ago 68% | 3 days ago 56% |
Advertisement
A and
Correlation & Price change
A.I.dvisor indicates that over the last year, A has been closely correlated with MTD. These tickers have moved in lockstep 86% of the time. This A.I.-generated data suggests there is a high statistical probability that if A jumps, then MTD could also see price increases.
TMO and
Correlation & Price change
A.I.dvisor indicates that over the last year, TMO has been closely correlated with MTD. These tickers have moved in lockstep 80% of the time. This A.I.-generated data suggests there is a high statistical probability that if TMO jumps, then MTD could also see price increases.